AstraZeneca
15 articles
Industry NewsAstraZeneca / OmnioseFierce Biotech
AstraZeneca Buys Collaboration Partner Omniose to Own Its Bioconjugate Vaccine Platform
- AstraZeneca acquired Omniose, a preclinical biotech whose platform assembles conjugate vaccines inside an engineered cell rather than through multi-step chemistry.
- Omniose becomes a wholly owned subsidiary within AstraZeneca's infectious disease unit; financial terms were not disclosed.
- The two had collaborated on vaccines against drug-resistant bacteria since January 2024.
Buying a partner you already work with is a classic de-risk-then-own move, and an undisclosed price suggests a small, platform-driven deal. Bacterial conjugate vaccines are where Pfizer and GSK are established, so the question is whether cell-based assembly is cheaper and more modular than chemical conjugation. Nothing clinical yet: this is a manufacturing and platform bet.
Industry NewsRhythm Pharmaceuticals / AstraZenecaBioSpace
Report: AstraZeneca Weighs Roughly $10B Bid for Rhythm Pharmaceuticals
- The Wall Street Journal, citing anonymous sources, reported that AstraZeneca offered about $10 billion, or $124 per share, for Rhythm; the deal is unconfirmed.
- BioSpace found no comment from either company, and Rhythm shares closed up 24% on Wednesday.
- Rhythm's MC4R drug Imcivree brought in $92.1 million in third-quarter sales and gained a hypothalamic obesity approval in March.
If accurate, this is AstraZeneca paying for a commercial rare-disease franchise rather than a pipeline option: Imcivree's $92.1 million quarter is modest against a $10 billion price, so the premium is really for MC4R biology and the hypothalamic obesity label. I'd read it as a hedge against crowded incretin obesity, buying a differentiated, orphan-protected niche. Rival bidders would likely prize the same scarcity.
Industry NewsAstraZenecaBioSpace
AstraZeneca launches three-year program targeting $1.5B in yearly savings
- AstraZeneca unveiled a three-year program aiming for roughly $1.5 billion in annual savings, with about $2 billion in upfront costs.
- Management said freed-up resources would be redirected toward the pipeline and growth areas, and that no layoffs are expected, though some roles may shift.
- The plan came with third-quarter revenue of $16.2 billion, up 7%, as the company works toward its $80 billion 2030 goal.
A $2B upfront bill for $1.5B in annual savings implies payback in about 16 months, yet the savings are only around 2% of annualized revenue. This is a funding mechanism, not a turnaround: AstraZeneca is self-financing pipeline and launch investment to bridge the gap to its $80B 2030 target, and the no-layoff pledge limits how deep the cuts can go.
Industry NewsAstraZenecaFierce Biotech
AstraZeneca Defends Sone-Ve Filing Case After Gastric Cancer PFS Miss
- Phase 3 CLARITY-Gastric01 tested the claudin 18.2 ADC sonesitatug vedotin in previously treated CLDN18.2-positive gastric cancer; it met its overall survival primary endpoint in third-line and later patients.
- The progression-free survival endpoint showed a favorable trend in the broader second-line-and-later population but was not statistically significant.
- An AstraZeneca executive told Fierce at ESMO that the dataset is robust enough for regulators; the company also floated broadening the positivity cutoff.
An OS win with a PFS miss is a defensible filing in a cancer where survival is the endpoint regulators and payers care about most, but the second-line label is now a negotiation rather than a given. With Takeda's rival ADC posting a clean dual win, AstraZeneca's first-mover claim in claudin 18.2 looks less secure than it did in July.
Industry NewsAstraZeneca / HUTCHMEDEndpoints News
AstraZeneca's Tagrisso plus Orpathys aims to keep EGFR lung cancer patients on Tagrisso after resistance
- At ESMO 2026 AstraZeneca presented data for Tagrisso (osimertinib) plus Orpathys (savolitinib) in EGFR-mutated non-small cell lung cancer that has become resistant to Tagrisso.
- The SAFFRON Phase 3 enrolled MET-driven patients; August toplines reported better progression-free and overall survival than platinum chemotherapy.
- A US filing has been submitted, and the combination is already approved in China.
MET amplification is a leading way Tagrisso fails, so a combination that lets patients stay on the backbone gives AstraZeneca a lifecycle play on its biggest lung franchise. The market is narrow, since it depends on testing for MET-driven resistance, and rivals with EGFR-MET bispecifics are chasing the same patients.
Industry NewsAstraZeneca / insitroFierce Biotech
AstraZeneca pays insitro $40M upfront for AI-driven liver and heart target discovery
- AstraZeneca and insitro signed a collaboration to find novel drug targets for liver and heart diseases using AI.
- Reported terms: a modest upfront payment of $40 million, with milestones taking the total to about $1.5 billion.
- Terms come from search-snippet reporting of the Fierce Biotech article, which could not be opened directly.
A small upfront against a large biobucks headline is the standard shape for platform-style target discovery: AstraZeneca pays for optionality, not assets. The partner choice shows where AZ sees the pharmacology bottleneck, in picking targets rather than designing molecules. I'd read it as another hedge alongside its other AI deals; the payoff comes only if the targets are credible.
Industry NewsAstraZenecaSTAT News
AstraZeneca opens $1B Kendall Square R&D site amid China dealmaking wave
- AstraZeneca opened a new R&D site in Boston's Kendall Square, marking a $1 billion investment.
- STAT frames the opening against a backdrop of heavy dealmaking with Chinese biotechs and uncertainty in the US biotech hub.
- Only the public STAT+ summary was available; site scope and headcount are not verified.
Planting a $1B flag in Kendall Square while licensing heavily from China looks like hedging: keep US discovery talent close even as external innovation shifts east. It's a capex signal, not a pipeline one, so the tell is whether the site hosts internal discovery or mostly integrates in-licensed assets.
Industry NewsSummit Therapeutics / AstraZeneca / Daiichi SankyoEndpoints News
Summit, AstraZeneca and Daiichi Sankyo to test ivonescimab plus Datroway, starting with Phase III in 1L TNBC
- Summit, AstraZeneca and Daiichi Sankyo announced a clinical collaboration combining ivonescimab (PD-1xVEGF bispecific) with Datroway (datopotamab deruxtecan, a TROP2-directed ADC).
- It starts with a Phase III study in first-line triple-negative breast cancer, with plans to expand to other settings including lung cancer.
- The companies will share trial costs, and each retains development and commercial rights to its own drug.
Three companies, two assets, and no one gives up rights: this is a cost-sharing structure, not a licensing deal. For Summit, pairing ivonescimab with a validated TROP2 ADC borrows AstraZeneca and Daiichi's TNBC credibility and trial muscle. For the big partners, it is a cheap hedge on the PD-1xVEGF class. I would want to see the control arm and endpoints before judging how much it de-risks.
Industry NewsAstraZeneca / Summit TherapeuticsFierce Biotech
AstraZeneca Takes a $2B Stake in Summit to Pair Ivonescimab with Its ADCs
- AstraZeneca is buying $2B of convertible preferred stock, giving it about 12% of Summit's common stock (about 10.6% fully diluted).
- The first combination pairs Summit's PD-1xVEGF bispecific ivonescimab with AstraZeneca's CLDN18.2-directed ADC in gastrointestinal cancers; a memorandum of understanding covers a broader program with more AstraZeneca ADCs.
This is AstraZeneca buying a seat rather than a pipeline: equity plus combination rights instead of an acquisition or license, keeping it close to a PD-1xVEGF class it doesn't own without paying for the asset outright. The bet is that ADC plus PD-1xVEGF combinations become a next oncology backbone, with AstraZeneca's ADC portfolio as the partner of choice. The broader MOU is non-binding, so definitive terms are the thing to watch.
Industry NewsAstraZeneca / Daiichi SankyoSTAT News
NHS England to Fund AstraZeneca's Enhertu After UK-US Pricing Deal
- NICE, which sets drug-funding recommendations for NHS England, will fund Enhertu (trastuzumab deruxtecan) for HER2-low metastatic or unresectable breast cancer after chemotherapy, reversing a July 2024 rejection on cost grounds.
- The reversal follows a UK-US pharmaceutical pricing deal that led NICE to raise its cost-effectiveness threshold and revise its appraisal methodology, making some costlier innovative drugs newly reimbursable.
- Enhertu, an antibody-drug conjugate co-developed by AstraZeneca and Daiichi Sankyo, has been reported in studies to meaningfully extend survival for this patient group versus chemotherapy alone, though the size of the benefit varies.
- An estimated 1,000 patients in England are expected to gain access, with treatment available within days of the decision.
NICE just permanently loosened its willingness-to-pay bar — as a negotiated line item in a bilateral trade deal, not a one-off cost-effectiveness review. That's the story here, not the roughly 1,000 patients gaining access: expect other governments squeezed between fiscal discipline and access pressure, and other pharma negotiators facing NICE, to point to this precedent. For AstraZeneca and Daiichi Sankyo, it de-risks Enhertu's ex-US rollout playbook: reimbursement fights in other cost-constrained markets (Canada, Australia, parts of Europe) just got a stronger comparator to cite. More broadly, this nudges the ceiling on what NICE will pay for high-cost ADCs and next-gen oncology assets generally, benefiting the wider oncology ADC pipeline queuing up for UK launch, not just this one drug. Watch whether AZ/Daiichi price other Enhertu indications, or future ADCs, against this new threshold.
Industry NewsAstraZeneca / Daiichi SankyoSTAT News
NHS England to Reimburse AstraZeneca's Enhertu for HER2-Low Breast Cancer After US-UK Pricing Deal
- Enhertu (trastuzumab deruxtecan), an AstraZeneca/Daiichi Sankyo HER2-targeting antibody-drug conjugate, will now be reimbursed by NHS England for HER2-low metastatic breast cancer.
- The move reverses NICE's July 2024 rejection of the drug for this indication, ending a years-long access dispute.
- It follows a new NICE agreement made possible by a broader U.S.-U.K. drug pricing deal (announced December 2025), which raised NICE's cost-effectiveness thresholds from about £20,000-£30,000 to £25,000-£35,000 per quality-adjusted life year.
- A new quality-of-life assessment methodology, published August 27, 2026, also supported the reassessment.
- About 1,000 women a year in England with HER2-low metastatic breast cancer are expected to now qualify, with studies reporting an average survival gain of roughly six months.
The science and data here are unchanged from NICE's 2024 rejection — this is a payer-economics win, not a clinical one, and it's easy to conflate the two. What actually moved was NICE's cost-effectiveness ceiling, from roughly £20-30K to £25-35K per QALY, engineered by the broader US-UK pricing deal, not new trial results. That's the real story: the first tangible commercial outcome traceable to that trade agreement, and it hands every company with a NICE-rejected asset a concrete playbook for reopening the case. Commercially, ~1,000 patients/year in England is a rounding error for AZ/Daiichi's global Enhertu franchise — the payoff is precedent, not revenue. Watch for ripple effects: rival ADCs and other HER2-low contenders now face a materially easier cost-effectiveness bar, reshaping competitive dynamics in an increasingly crowded ADC pipeline.
Industry NewsAstraZenecaSTAT News
AstraZeneca's Camizestrant Falls Short in Broad First-Line Breast Cancer Trial
- AstraZeneca's Phase III SERENA-4 trial tested camizestrant (Etcamah) plus palbociclib against anastrozole plus palbociclib as a first-line treatment for 1,371 patients with newly diagnosed ER-positive, HER2-negative advanced or metastatic breast cancer.
- The study enrolled a biomarker-unselected population, meaning patients were not screened for specific tumor mutations before treatment.
- SERENA-4 missed its primary endpoint of progression-free survival, though camizestrant showed a numerical trend favoring it over the anastrozole combination.
- The result contrasts with the separate Phase III SERENA-6 trial, which succeeded in a narrower population of patients with emerging ESR1 mutations.
- Just over a week earlier, on September 4, 2026, the FDA granted camizestrant accelerated approval based on SERENA-6 data, specifically for that ESR1-mutant first-line setting.
- Together, the trials indicate camizestrant's benefit may be concentrated in biomarker-selected patients rather than the broader first-line breast cancer population.
SERENA-4's miss against SERENA-6's win draws exactly the line AZ didn't want drawn: camizestrant works, but only with ESR1-mutant selection — putting it on the same narrow-indication footing as the rest of the oral SERD class, not ahead of it. Giredestrant and peers are chasing the same biomarker-defined slice, so this doesn't buy AZ a competitive edge, just confirms nobody's cracked broad first-line yet. Peak-sales models built on all-comers use need to come down hard, replaced by a smaller, testing-gated population — meaning AZ now funds ESR1 diagnostic uptake and retrains oncologists to test before prescribing, adding commercial friction. Broadly, it's another sign precision oncology, not blockbuster breadth, is the default ceiling for this class — AZ's oncology bet now looks like defending biomarker niches, not chasing first-line share.
Industry NewsAstraZenecaFiercePharma
FDA Approves AstraZeneca's Etcamah in First ctDNA-Triggered Breast Cancer Treatment Switch
- Camizestrant, sold as Etcamah, is AstraZeneca's oral SERD, approved in combination with a CDK4/6 inhibitor for HR-positive, HER2-negative advanced breast cancer.
- The FDA's accelerated approval applies only when a blood-based ctDNA test detects an emerging ESR1 resistance mutation during ongoing first-line aromatase-inhibitor-plus-CDK4/6-inhibitor therapy, before any scan-confirmed disease progression.
- This is the first FDA approval in which a ctDNA liquid-biopsy signal alone, rather than radiographic progression, triggers a switch to a new regimen.
- FDA simultaneously approved a companion diagnostic, the Guardant360 CDx ctDNA assay, to identify the ESR1 mutation guiding this switch.
- Trial data cited showed the camizestrant combination improved progression-free survival versus continuing the prior regimen after the mutation appeared, though accelerated approval remains subject to confirmatory trial verification.
AstraZeneca just banked a regulatory first that's harder to copy than a molecule: switching therapy off a blood test before scans show progression. That head start matters in HR+/HER2- breast cancer, the biggest and most crowded segment in oncology, because rivals chasing ESR1-resistance plays now need their own drug plus their own FDA-blessed ctDNA pathway — a two-part bar, not one. Pairing with Guardant360 CDx also means AstraZeneca doesn't own the whole value chain; commercial success now hinges on oncologists actually ordering serial ctDNA testing during first-line therapy — a workflow change, not just a prescribing choice. If adoption sticks, AZ has a template — earlier, biomarker-triggered switching — to extend toward other resistance mutations and assets, turning a single approval into a broader precision-oncology moat rather than a one-off label.
Industry NewsAstraZenecaFierce Biotech
Tozorakimab Notches Third Phase III Win in COPD
- AstraZeneca reported full results from two Phase III trials, OBERON and TITANIA, testing tozorakimab, an anti-IL-33 monoclonal antibody, added to standard inhaled therapy for chronic obstructive pulmonary disease (COPD).
- Across both trials, tozorakimab substantially cut moderate-to-severe exacerbation rates versus placebo in former smokers, with meaningful reductions also seen in a broader population including current smokers.
- The antibody is engineered to engage two separate IL-33 signaling pathways at once, a mechanism AstraZeneca positions as differentiating it from earlier single-pathway IL-33 drugs.
- This marks tozorakimab's third positive Phase III readout; results were presented at the European Respiratory Society Congress in Barcelona and published simultaneously in the New England Journal of Medicine.
- AstraZeneca is targeting US regulatory approval, expected in early 2027.
Three-for-three in Phase III is the real headline here — a track record like that de-risks tozorakimab in a way single-pathway IL-33 rivals (think itepekimab, astegolimab) can't yet match, strengthening AstraZeneca's hand with regulators and payers alike. The dual-pathway engineering pitch is the commercial wedge: as COPD biologics get crowded, "we hit both arms of IL-33 signaling" is a differentiation story sales teams can actually use. Strategically, this is AstraZeneca building a respiratory biologics franchise in a market that's long been underserved beyond inhalers — COPD's patient pool dwarfs severe asthma's. And running NEJM publication simultaneously with the ERS presentation isn't routine; it's a credibility move, front-loading peer-reviewed validation well ahead of the 2027 filing to pre-empt scrutiny.
Industry NewsAlnylam / AstraZenecaSTAT News
Alnylam Defends ATTR-CM Franchise After Rival's Wainua Trial Stumbles
- Full Phase 3 CARDIO-TTRansform results, presented at ESC Munich, showed AstraZeneca/Ionis's TTR silencer eplontersen (Wainua) failed to significantly cut cardiovascular death/events in ATTR-CM over roughly 140 weeks (rate ratio 0.89, p=0.277).
- Critically, patients already on a stabilizer (Pfizer's Vyndaqel, BridgeBio's Attruby) saw no added benefit from Wainua; only silencer-monotherapy patients showed a nominal gain.
- That subgroup split is uncomfortable for Alnylam, whose Amvuttra and pipeline candidate nucresiran are the same drug class and increasingly used alongside stabilizers.
- Alnylam shares fell nearly 5%.
- Executives countered that Amvuttra achieves deeper TTR knockdown than eplontersen and that nucresiran's larger TRITON-CM trial should avoid Wainua's pitfalls.
The subgroup data is the real story: if silencers add nothing once patients are already stabilized, the industry's drift toward stabilizer-plus-silencer combos loses its evidence base, and AZ/Ionis must reposition Wainua as monotherapy — a much smaller, harder-to-sell market. That's a strategic problem, not just a trial miss, and it makes Intellia's one-and-done knockdown pitch relatively more attractive. Alnylam's rebuttal (deeper knockdown, a bigger trial) is the self-interested defense you'd expect from a company facing guilt-by-association, resting on cross-trial comparisons Alnylam itself is asserting, not independent data — treat "deeper knockdown" as a hypothesis until TRITON-CM reads out. Nucresiran's margin for error just got narrower. Watch prescriber messaging: whoever wins the "silencer as add-on vs. backbone" argument sets ATTR-CM's standard of care.